Best Stocks Under $10 Right Now → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Written by MarketBeat StaffAugust 1, 2022How Is a Company’s Share Price Calculated?Should Investors Buy Stocks Under $10?What Are the Rewards of Stocks Under $10?What Are the Risks of Buying Stocks Under $10?What Are the Best Stocks Under $10?A common mistake among novice investors is confusing an undervalued stock with a cheap stock. When a stock trades under $5 (often called penny stocks), it can be easy for an investor to understand why the stock carries such a low price. But when a stock trades below $10, a little more research is required. This is particularly true when the broader market is in a sell-off. Before attempting to buy stocks that are trading for less than 10 dollars, there are some important things to know. How Is a Company’s Share Price Calculated? If you’re an experienced investor this is just a basic review. But if you’re a relatively new investor this may help answer a lot of questions. To understand why buying stocks under $10 can come with an elevated risk you need to understand how a company’s stock price is calculated. There are two data points to look for. The first is a company’s market capitalization (or market cap). That is a rough estimation of how much a company is worth. The second number is the number of outstanding shares (also called shares outstanding – the meaning is the same). This is, as the name suggests, the number of common shares available to be bought. To calculate a company’s stock price, you divide the company’s current market capitalization by its number of outstanding shares. Here’s an example that keeps the math easy. A stock that is valued at $100 million and has 1 million outstanding shares has a share price of $100. But a stock that is valued at $100 million and has 100 million outstanding shares has a share price of $10. The important thing to take away from that example is a stock’s price does not necessarily reflect the market value of the company. Now here’s a real world example. On March 27, General Electric (NYSE:GE) had a market cap of $66.37 billion. The company had 8.74 billion outstanding shares. When you divide the market cap by the outstanding shares you get 7.59. 66.37/8.74 = 7.59 This means at that moment, one share of GE stock was valued at $7.59. Should Investors Buy Stocks Under $10? The simple answer is “Of course you should.” A common fallacy among even the most experienced investors is failing to understand the difference between a stock that is cheap and one that is undervalued. It’s an interesting aspect of human psychology. A stock that is trading at $200 could decline by 25% and investors will swoop in to buy it “on sale”. But if a $12 stock drops 20% it becomes untouchable. The problem with this approach is it assumes that a high price is good and a low price is bad. And in fairness, that can be true. Many stocks that trade under $10 do so because they present obvious and fundamentally problematic issues that are suppressing their growth. So if you’re an investor who is looking to buy stocks under $10 is be sure you’re ready, and able, to do some research. Simply throwing your hard-earned money at a stock because you’ve heard the mantra “buy low, sell high” is foolish. But the same can be said of investing in any stock. And if you’re reading this article, I hope you already understand that stocks over time can be an excellent and sound investment. Stock prices, no matter the price, can fluctuate wildly. But over time, investing in stocks has proven to be the most reliable path to reaching your financial goals. And the simple truth is that a stock that is trading under $10 can offer you the ability to make huge gains. But that is, if you know what to look for. Fortunately, in this article, we’ve done a lot of that research for you. But there is one caveat about investing in stocks under $10. This should only make up a small portion of the stock portion of your portfolio. The majority of your investment in equities (another name for stocks) should focus on solid, stable companies. And depending on your investment style, you should look for companies that pay a dividend. You should also not invest in stocks under $10 to replace money you have set aside in bonds or cash. This should be money that you are already investing in the market. What Are the Rewards of Stocks Under $10? The reward of buying stocks under $10 is the opportunity for growth. If you can buy 1000 shares of a stock that is trading at $8, you would only need the stock to increase in value by $8 to double your investment. If you were That, however, is easier said than done. And many investors have seen that $8,000 investment evaporate as they bought shares of a falling knife. Still, if investors can find the right stock, stocks under $10 are one of the best ways to capture a significant gain without a large investment. That brings up a second point. Stocks under $10 are more accessible for investors without a lot of money to put into the market. Robinhood and other trading apps are designed on this principle. If you only have a small amount of money to invest, you don’t have to put all your eggs in one basket. In practical terms, and investor with $10,000 to invest could buy over 150 shares a stock that is currently trading below $7 a share. This also makes stocks under $10 a great option for diversification. Not only can you look at different sectors, but you can also dabble in international stocks. What Are the Risks of Buying Stocks Under $10? Here are some of the most common risks of buying stocks under $10: Share dilution - Generally, the number of outstanding shares is driven by simple supply and demand. A company that issues a solid earnings report, or comes out with a new product, etc. will see their outstanding shares decline because there will be more buyers than sellers.In other words, the stock is harder to buy. If an investor wants to buy it, a seller will demand a higher price to let their shares go. And when there are more sellers than buyers, there will be a higher number of outstanding shares. In other words, sellers have to accept a lower price for the shares they purchased to entice a buyer to buy.However, when a company gets into financial trouble, it becomes difficult for them to get loans. When a company has limited free cash flow (FCF), they are seen as a credit risk. This simply means lenders believe there is a high probability that the company will default on the loan.When this happens, one strategy they may execute is to issue more shares. This almost always dilutes the value of the existing shares, which in turn drives the price down further. Increased competition - Young startup companies often have a first mover advantage. Because they are creating a new market, they have no competition and have no price pressure. However, as more competitors enter the market, a company may face pressure both on the price they charge and their profit margin. If the company is slow to adapt to the competition, their stock price may sink to extremely low levels. The company operates in a cyclical industry - A retailer may see their stock spike during the holiday season as investors anticipate greater revenue and profit. However, for the remainder of the year, the company may not be able to sustain that revenue. That’s another reason the stock may sink. The stock is low- to no-growth stock - If you look at the price history of a stock, it may just trade in a specific range. In that case, a stock under $10 may still be a worthwhile investment if it pays a nice dividend. What Are the Best Stocks Under $10? If you’ve followed this article and understand both the pros and cons of stocks under $10, let’s take a look at how you can put that information to work in the middle of one of the greatest stock sell-offs in history. On the one hand, there are a number of quality companies that have seen their share price reach uncomfortably low levels. But some of these stocks are in industries like hospitality that have been particularly affected by the coronavirus. And while these stocks are generally perceived to see increased, pent-up demand once the coronavirus threat recedes, it may be some time before this increased demand shows up in the stock price. Value investing opportunities do exist—if you're looking in the right places. Putting together a list of the best stocks under $10.00 requires investors to do their homework. At a price of under $10, these companies are not penny stocks. In fact many companies have a large market cap. But just because a stock is trading for a low price doesn’t make it a great value. One of the biggest assets an investor can have is time. If you’ve done your due diligence and believe in the overall financial health and direction of the company, buying stocks under $10 can be very profitable. If you have the time and patience to hold the stock through many economic cycles, here are some stocks to consider. Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates. Top Headlines and OffersBargain Alert: Amazon and Its 35% UpsideMay 31, 2024 10:12 AMView Bargain Alert: Amazon and Its 35% Upside3 Stocks Insiders are Buying That Should be on Your RadarMay 28, 2024 1:03 PMView 3 Stocks Insiders are Buying That Should be on Your RadarSHOCKING Crypto Leak…From Crypto 101 Media(Ad)View SHOCKING Crypto Leak…Costco Wholesale Can Hit New Highs; A Rebound Is ComingMay 31, 2024 11:35 AMView Costco Wholesale Can Hit New Highs; A Rebound Is ComingStock market today: Wall Street rallies to close out a bloom-filled MayMay 31, 2024 2:13 AMView Stock market today: Wall Street rallies to close out a bloom-filled MayDecker's Stock Surges Like NVIDIA Through $1,000 on Robust GrowthMay 29, 2024 9:57 AMView Decker's Stock Surges Like NVIDIA Through $1,000 on Robust GrowthSHOCKING Crypto Leak…From Crypto 101 Media(Ad)View SHOCKING Crypto Leak…Salesforce Falls 25% Into A Once in a Lifetime OpportunityMay 30, 2024 10:45 AMView Salesforce Falls 25% Into A Once in a Lifetime OpportunityChevron Eyes Hess, Exxon Resists: Here's the TradeMay 31, 2024 10:36 AMView Chevron Eyes Hess, Exxon Resists: Here's the TradeAI Is Booming, But Not For These Stocks …YetMay 31, 2024 9:49 AMView AI Is Booming, But Not For These Stocks …YetPure Storage Stock Spikes and Analysts are Jumping on BoardMay 30, 2024 12:07 PMView Pure Storage Stock Spikes and Analysts are Jumping on BoardFoot Locker’s Quarter Sends Doubters RunningMay 31, 2024 11:47 AMView Foot Locker’s Quarter Sends Doubters RunningAll Headlines Show: Stocks Under $0.50 Stocks Under $1.00 Stocks Under $2.00 Stocks Under $5.00 Stocks Under $10.00 Stocks Under $20.00 Stocks Under $30.00 Stocks Under $50.00 Stocks On Sale #1 - Ocuphire PharmaNASDAQ:OCUPStock Price: $1.68P/E Ratio: -3.43Market Cap: $43.55 millionAverage Trading Volume: 205,460 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $18.75 (1,016.1% Upside)Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan. Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. #2 - PMV PharmaceuticalsNASDAQ:PMVPStock Price: $1.82 (+$0.03)P/E Ratio: -1.37Market Cap: $93.62 millionAverage Trading Volume: 519,665 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.75 (215.9% Upside)PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.#3 - Clean Energy FuelsNASDAQ:CLNEStock Price: $3.13 (+$0.13)P/E Ratio: -8.94Market Cap: $698.80 millionAverage Trading Volume: 1.66 million sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.60 (78.9% Upside)Clean Energy Fuels Corp. provides natural gas as alternative fuels for vehicle fleets and related fueling solutions in the United States and Canada. It supplies renewable natural gas (RNG), compressed natural gas (CNG), and liquefied natural gas (LNG) for medium and heavy-duty vehicles; and offers operation and maintenance services for public and private vehicle fleet customer stations. The company also designs, builds, operates, and maintains vehicle fueling stations; and sells and services compressors and other equipment that are used in RNG production and fueling stations. In addition, it transports and sells CNG, RNG, and LNG through virtual natural gas pipelines and interconnects; sells U.S. federal, state, and local government credits, such as RNG as a vehicle fuel, including Renewable Identification Numbers and Low Carbon Fuel Standards credits; and obtains federal, state, and local credits, grants, and incentives. Further, the company focuses on developing, owning, and operating dairy and other livestock waste RNG projects. It serves heavy-duty trucking, airports, refuse, public transit, industrial, and institutional energy users, as well as government fleets. Clean Energy Fuels Corp. was incorporated in 2001 and is headquartered in Newport Beach, California.#4 - Scholar RockNASDAQ:SRRKStock Price: $9.39P/E Ratio: -4.49Market Cap: $748.89 millionAverage Trading Volume: 801,686 sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $25.17 (168.0% Upside)Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.#5 - Zura BioNASDAQ:ZURAStock Price: $5.25 (-$0.12)Market Cap: $228.87 millionAverage Trading Volume: 264,924 sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $18.83 (258.7% Upside)Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.#6 - Aquestive TherapeuticsNASDAQ:AQSTStock Price: $2.88 (-$0.03)P/E Ratio: -6.86Market Cap: $262.19 millionAverage Trading Volume: 2.09 million sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $8.00 (177.8% Upside)Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Did you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now.#7 - Mind Medicine (MindMed)NASDAQ:MNMDStock Price: $8.80 (-$0.01)P/E Ratio: -2.99Market Cap: $618.38 millionAverage Trading Volume: 1.74 million sharesConsensus Rating: Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $19.00 (115.9% Upside)Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.#8 - ArdelyxNASDAQ:ARDXStock Price: $6.86 (+$0.08)P/E Ratio: -24.50Market Cap: $1.60 billionAverage Trading Volume: 5.90 million sharesConsensus Rating: Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $12.81 (86.8% Upside)Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.#9 - Actinium PharmaceuticalsNYSEAMERICAN:ATNMStock Price: $8.15 (+$0.04)P/E Ratio: -4.77Market Cap: $242.71 millionAverage Trading Volume: 319,433 sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $25.60 (214.1% Upside)Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.#10 - SimilarwebNYSE:SMWBStock Price: $7.69 (-$0.03)P/E Ratio: -30.76Market Cap: $604.82 millionAverage Trading Volume: 173,756 sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $10.60 (37.8% Upside)Similarweb Ltd. provides cloud-based digital intelligence solutions in the United States, Europe, the Asia Pacific, the United Kingdom, Israel, and internationally. The company offers digital research intelligence solutions for its customers to benchmark performance against competitors and market leaders, analyze trends in the market, conduct deeper research into specific companies, and analyze audience behavior; and digital marketing intelligence solutions for its customers to understand their competitors' online acquisition strategies in each marketing channel, and optimize their own strategies. It also provides sales intelligence solutions for its customers to access relevant buying signals and digital insights of their customers to generate leads quickly; and shopper intelligence solutions for its customers to analyze a view of their customers' digital journeys, monitor consumer demand, increase brand visibility in the search process, and optimize category and product level conversion in the purchase process. In addition, the company offers investor intelligence solutions for its customers to access an end-to-end view of market, sector, and company performance to ideate and monitor investment opportunities; forecast market performance; and perform due diligence. Further, it provides data-as-a-service and advisory services. The company serves retail, consumer packaged goods, consumer finance, consultancies, marketing and advertising agencies, media and publishers, business-to-business software, payment processors, travel, and institutional investors. Similarweb Ltd. was incorporated in 2009 and is headquartered in Givatayim, Israel.#11 - Man GroupOTCMKTS:MNGPFStock Price: $3.55 (+$0.04)P/E Ratio: 121.21Average Trading Volume: 1,233 sharesDividend Yield: 3.50%<Consensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $128.50 (3,519.7% Upside)Man Group Limited is a publicly owned investment manager. The firm provides long-only and alternative investment management services worldwide. It offers a range of liquid investment products and solutions, which include quantitative, multi-manager and discretionary investment styles, and span across various asset classes, like equity, real estate, currency, credit, volatility, and commodities. The firm distributes its products and solutions directly to institutions and to private investors through a global network of intermediaries. Man Group Limited was founded in 1783 and is based in St. Helier, Jersey with an additional office in London, United Kingdom.[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Did you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now.#12 - KingfisherOTCMKTS:KGFHYStock Price: $6.71 (+$0.01)Market Cap: $6.25 billionAverage Trading Volume: 417,720 sharesDividend Yield: 5.89%<Consensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AKingfisher plc, together with its subsidiaries, supplies home improvement products and services primarily in the United Kingdom, Ireland, France, and internationally. The company also offers property investment, finance, digital, sourcing, and IT services. It also operates retail stores under the B&Q, Castorama, Brico Dépôt, Screwfix, TradePoint, and Koçtas brands. The company sells its products through stores and e-commerce channels. Kingfisher plc was incorporated in 1982 and is headquartered in London, the United Kingdom.#13 - Uranium EnergyNYSEAMERICAN:UECStock Price: $7.14 (-$0.13)P/E Ratio: -714.00Market Cap: $2.89 billionAverage Trading Volume: 7.34 million sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $8.80 (23.2% Upside)Uranium Energy Corp., together with its subsidiaries, engages in exploration, pre-extraction, extraction, and processing uranium and titanium concentrates in the United States, Canada, and Paraguay. It owns interests in the Palangana mine, Goliad, Burke Hollow, Longhorn, and Salvo projects located in Texas; Anderson, Workman Creek, and Los Cuatros projects situated in Arizona; Dalton Pass and C de Baca project located in New Mexico; Roughrider, Shea Creek, Christie Lake, Horseshoe-Raven, Hidden Bay, Diabase, West Bear, JCU, and other project located in Canada; and Yuty, Oviedo, and Alto Paraná titanium projects in Paraguay. The company was formerly known as Carlin Gold Inc. and changed its name to Uranium Energy Corp. in January 2005. Uranium Energy Corp. was incorporated in 2003 and is headquartered in Corpus Christi, Texas.#14 - Paragon 28NYSE:FNAStock Price: $7.69 (-$0.09)P/E Ratio: -11.83Market Cap: $637.89 millionAverage Trading Volume: 566,652 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $16.75 (117.8% Upside)Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.#15 - Iovance BiotherapeuticsNASDAQ:IOVAStock Price: $8.88 (-$0.12)P/E Ratio: -4.93Market Cap: $2.48 billionAverage Trading Volume: 7.88 million sharesConsensus Rating: Buy (10 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $24.64 (177.4% Upside)Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.#16 - AlightNYSE:ALITStock Price: $7.75 (+$0.24)P/E Ratio: -12.50Market Cap: $4.35 billionAverage Trading Volume: 6.79 million sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $12.00 (54.8% Upside)Alight, Inc. provides cloud-based integrated digital human capital and business solutions worldwide. The company operates through two segments, Employer Solutions and Professional Services. The Employer Solutions segment offers employee wellbeing, integrated benefits administration, healthcare navigation, financial wellbeing, leave of absence management, retiree healthcare and payroll; and operates AI-led capabilities software. The Professional Services segment offers consulting offerings, such as cloud advisory, deployment, and optimization services for cloud platforms. The company provides Alight Worklife, an intuitive, cloud-based employee engagement platform. Its solutions enable employees to enrich their health, wealth, and wellbeing that helps organizations achieve a high-performance culture. Alight, Inc. was founded in 2020 and is based in Lincolnshire, Illinois.[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Did you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now.#17 - EntainOTCMKTS:GMVHFStock Price: $8.29 (-$0.63)P/E Ratio: 17.76Average Trading Volume: 2,140 sharesDividend Yield: 8.81%<Consensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AEntain Plc operates as a sports-betting and gaming company. The company provides online and multi-channel betting under the Ladbrokes name; street and online betting under the Coral name; online sports betting, casino, and gaming under the Eurobet name; scores, sports information, editorial and social content, and sports focused free-to play games under the 365Scores name; sports betting and games under the SuperSport and BetCity names; online betting under the bwin name; and sports betting, poker, and casino games under the Crystalbet name. It also offers online casino and sports betting under the Optibet name; online bingo under the Gala Bingo; online bingo under the Foxy Bingo name; sportsbetting and gaming under the Sports Interaction and Vistabet names; games under the Nutz and laimz names; game under the boost casino name; online gaming under the Borgata Bingo name; bingo and casino under the Foxy Games name; online bingo, sportsbook, casino, and poker under the betboo; and management software solutions for racing and sportsbooks under the Stadium name. In addition, the company operates sports betting and iGaming under the BetMGM and Sportingbet names; sports betting under the Ladbrokes Australia, TAB NZ, and STS names; Gioco Digitale, a casino platform; Ladbrokes.be, a sports betting outlet; online casino under the NinjaCasino and PartyCasino names; casino and live casino under the Gala Casino name; online poker under the partypoker name; sports under the Neds and Klondaika names; and iGaming platform under the Finnplay name. Entain Plc was incorporated in 2004 and is headquartered in Douglas, Isle of Man.#18 - Controladora Vuela Compañía de AviaciónNYSE:VLRSStock Price: $7.97 (-$0.02)P/E Ratio: 8.22Market Cap: $699.65 millionAverage Trading Volume: 482,590 sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $13.01 (63.3% Upside)Controladora Vuela Compañía de Aviación, S.A.B. de C.V., through its subsidiary, Concesionaria Vuela Compañía de Aviación, S.A.P.I. de C.V., provides air transportation services for passengers, cargo, and mail in Mexico and internationally. The company operates approximately 590 daily flights on routes connecting 43 cities in Mexico, 22 cities in the United States, 4 cities in Central America, and 2 cities in South America. As of December 31, 2022, it leased 116 aircrafts and 23 spare engines. The company also offers merchandising, travel agency, and loyalty program, as well as specialized and aeronautical technical services. Controladora Vuela Compañía de Aviación, S.A.B. de C.V. was incorporated in 2005 and is headquartered in Mexico City, Mexico.#19 - enGeneNASDAQ:ENGNStock Price: $8.79 (-$1.71)Market Cap: $383.08 millionAverage Trading Volume: 52,378 sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $34.40 (291.4% Upside)enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.#20 - Newpark ResourcesNYSE:NRStock Price: $8.48 (+$0.43)P/E Ratio: 47.11Market Cap: $722.50 millionAverage Trading Volume: 653,963 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $11.00 (29.7% Upside)Newpark Resources, Inc. provides products, rentals, and services primarily to the oil and natural gas exploration and production (E&P) industry. It operates through two segments, Fluids Systems and Industrial Solutions. The Fluids Systems segment provides drilling, completion, and stimulation fluids products and related technical services to customers primarily in the North America, Europe, the Middle East, and Africa, as well as other countries in the Asia Pacific and Latin America. The Industrial Solutions segment offers composite matting system rentals utilized for temporary worksite access; related site construction and services to customers in various markets, including power transmission, E&P, pipeline, renewable energy, petrochemical, construction, and other industries primarily in the United States and Europe; recyclable composite mats to customers worldwide; and access road construction, site planning and preparation, environmental protection, erosion control, and site restoration services. The company was incorporated in 1932 and is headquartered in The Woodlands, Texas.#21 - easyJetOTCMKTS:ESYJYStock Price: $5.96 (+$0.07)P/E Ratio: 1.32Average Trading Volume: 10,526 sharesDividend Yield: 2.60%<Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AeasyJet plc operates as a low-cost airline carrier in Europe. The company engages in the provision of holiday packages; aircraft trading and leasing activities; development of building projects; financing and insurance business; and tour operator activities. easyJet plc was founded in 1995 and is headquartered in Luton, the United Kingdom.#22 - Crescent Point EnergyNYSE:CPGStock Price: $8.59 (-$0.01)P/E Ratio: -107.36Market Cap: $5.32 billionAverage Trading Volume: 5.65 million sharesDividend Yield: 3.94%<Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $13.81 (60.8% Upside)Crescent Point Energy Corp. explores, develops, and produces oil and gas properties in Canada and the United States. The company focuses on crude oil, tight oil, natural gas liquids, shale gas, and natural gas reserves. Its properties are located in the provinces of Saskatchewan, Alberta, British Columbia, and Manitoba; and the states of North Dakota. Crescent Point Energy Corp. was incorporated in 1994 and is headquartered in Calgary, Canada.#23 - ORIC PharmaceuticalsNASDAQ:ORICStock Price: $8.99 (+$0.06)P/E Ratio: -4.99Market Cap: $606.11 millionAverage Trading Volume: 520,961 sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $20.00 (122.5% Upside)ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.#24 - Spire GlobalNYSE:SPIRStock Price: $9.15 (-$0.21)P/E Ratio: -2.63Market Cap: $222.53 millionAverage Trading Volume: 448,781 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $17.60 (92.3% Upside)Spire Global, Inc. provides subscription-based data, insights, predictive analytics, and related project-based services worldwide. The company offers satellite-based aircraft tracking data to power applications, drive decision making, and improve cost efficiencies; data, insights, and predictive analytics for highly accurate ship monitoring, real-time and near real-time vessel updates, port operations, ship safety and route optimization; and space-based data, AI-powered insights, and predictive weather analytics for accurate weather forecasting. It serves maritime, weather, aviation, and space services industries. The company was formerly known as Nanosatisfi, Inc. and changed its name to Spire Global, Inc. in July 2014. Spire Global, Inc. is headquartered in Vienna, Virginia.#25 - Mullen GroupOTCMKTS:MLLGFStock Price: $9.47 (-$0.07)P/E Ratio: 9.51Average Trading Volume: 1,511 sharesDividend Yield: 6.51%<Consensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $14.65 (54.7% Upside)Mullen Group Ltd. provides a range of trucking and logistics services in Canada and the United States. The Less-Than-Truckload segment delivers general freight consisting of smaller shipments, packages, and parcels; and pharmaceutical and package products. The Logistics & Warehousing segment offers full truckload, specialized transportation, warehousing, and fulfillment centers that handle e-commerce transactions and transload facilities for intermodal and bulk shipments; technology solutions, including transportation, inventory, and warehouse management systems; and warehousing and distribution services. The Specialized & Industrial Services segment provides specialized equipment and services to the oil and natural gas, environmental, construction, pipeline, utility, telecom, and civil industries; and specialized services comprising water management, environmental services, pipeline and civil construction, Industrial cleaning and turnaround services, fluid management, and municipal development and emergency support services, as well as drilling and drilling related services. The U.S. & International Logistics segment provides logistics services through professional representatives and station agents. This segment also owns SilverExpress, a proprietary integrated transportation management platform. Mullen Group Ltd. was founded in 1949 and is headquartered in Okotoks, Canada. More Stock Ideas from MarketBeat Stock Lists: 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks: Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange: NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEMKT Stocks NYSEARCA Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas: MarketBeat Week in Review – 5/27 - 5/31 Foot Locker’s Quarter Sends Doubters Running Costco Wholesale Can Hit New Highs; A Rebound Is Coming Chevron Eyes Hess, Exxon Resists: Here's the Trade Bargain Alert: Amazon and Its 35% Upside AI Is Booming, But Not For These Stocks …Yet PayPal Has a New Growth Road Ahead For Investors, Ready to Rally? Okta, Inc. Stock Falls To Critical Level: What Happens Next? Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.